# OnCo record card (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/card/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "card", "NCT02485691" ;
  schema:name "CARD"@en ;
  schema:alternateName "CARD"@en, "cabazitaxel against a second androgen receptor pathway inhibitor"@en ;
  schema:description "Settled the commonest argument in advanced prostate cancer. When one hormone tablet stops working quickly, switching to the other one is much worse than moving to chemotherapy."@en ;
  schema:url <https://onco.cc/trials/card/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02485691>, <https://doi.org/10.1056/NEJMoa1911206>, <https://www.nice.org.uk/guidance/ta391> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/cabazitaxel/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/arpi/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/ar-v7/> ;
  onco:trials <https://onco.cc/trials/tropic/>, <https://onco.cc/trials/proselica/>, <https://onco.cc/trials/therap/>, <https://onco.cc/trials/vision/> .